Description
This invention describes a mouse model for neuronal proliferation, bradykinesia and seizures which lack p19ink4d and p27kip1 proteins. It is a useful model for identifying potential therapeutic agents for treatment of hearing and balance disorders.
Keywords
p19ink4d, p27Kip1
Granted Patents or Published Applications
U.S. Patent Nos. 6,245,965; 6,589,505
Related Scientific References
Chen P, et al., “Progressive hearing loss in mice lacking the cyclin-dependent kinase inhibitor Ink4d”, Nat Cell Biol. 5(5):422-6 (2003);
Cunningham J, et al., “The cyclin-dependent kinase inhibitors p19(Ink4d) and p27(Kip1) are coexpressed in select retinal cells and act cooperatively to control cell cycle exit”, Mol Cell Neurosci. 19(3):359-74 (2002);
Zindy F, et al., “Postnatal neuronal proliferation in mice lacking Ink4d and Kip1 inhibitors of cyclin-dependent kinases”, Proc Natl Acad Sci 9;96(23):13462-7 (1999);
Zindy F, et al., “Expression of INK4 inhibitors of cyclin D-dependent kinases during mouse brain development,” Cell Growth & Differ. 8(11):1139-50 (1997).
Licensing Opportunities
We are currently seeking licensing opportunities in all fields for this technology. Contact: chad.riggs@stjude.org
Related Links
Technologies
- Activation of Prodrugs by Carboxylesterase (SJ-98-0001)
- Alternate mTOR Pathway (SJ-09-0021)
- ARF and HDM2 interaction domains (SJ-01-0016)
- Assay for ATM Kinase Modulation (SJ-02-0008)
- BMP Compounds for treating diseases caused by defective or diminished BMP signaling (Medulloblastoma) - (SJ-15-0008)
- Caspase 1 inhibition to overcome glucocorticoid resistance (SJ-13-0039)
- CD7 CAR placed in CD7neg memory cells (SJ-15-0020)
- DCN1 Inhibitors (SJ-16-0002)
- Defects in LC3-associated phagocytosis (LAP) associated with Lupus (SJ-16-0025)
- Discovery of a fluorescent vinblastine analog with high affinity to the human pregnane X receptor (hPXR) Ligand (SJ-13-0009)
- Discovery of a novel inhibitor of constitutive androstane receptor (CAR) that does not activate pregnane X receptor (PXR) (SJ-14-0039)
- DON and small molecule Bcl-2 family antagonists treating glutamine addicted cell lines for Neuroblastomas and Ewing sarcomas (SJ-13-0026)
- Hematopoietic progenitor cell lines with myeloid and lymphoid potential (SJ-11-0003)
- Improving HSC Engraftment by Inhibiting GASP Genes (SJ-16-0029)
- Interaction of Reelin With Very Low Density Lipoprotein (VLDL) Receptor (SJ-98-0045)
- Method for Enhancing Recombinant Antibody Production (SJ-08-0032)
- Methods and compositions for the prevention and treatment of hearing loss using CDK2 inhibitors (SJ-14-0028)
- Methods for Diagnosing and Treating Learning or Mental Disorders with the SERCA2 Protein and miRNAs that regulate SERCA2 Levels (SJ-10-0003 and SJ-12-0020)
- Ozz, A Protein That Regulates Development and Function of Muscle Cells (SJ-99-0010)
- Rapid Cloning of T Cell Receptors (SJ-16-0001)
- Regulating p53 Translation and Function (SJ-05-0002)
- SCCRO Peptide Inhibitor (SJ-11-0014)
- Use of specific retinoid receptor agonists and antagonists as cancer therapies (SJ-14-0011)
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.